Can cutting nerves stop deadly heart rhythms in chagas patients?
NCT ID NCT04239144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a procedure called bilateral sympathectomy, which cuts certain nerves to the heart, in 45 Chagas disease patients with implantable defibrillators (ICDs) who had frequent dangerous heart rhythms. Participants were randomly assigned to receive the nerve-cutting procedure, standard medication, or catheter ablation. The goal was to see if the nerve procedure could reduce the number of heart rhythm episodes and improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bilateral sympathectomy (nerve-cutting procedure via video-assisted thoracoscopy)
- What this could lead to
- If it works, this could offer a new treatment option for controlling life-threatening heart rhythms in Chagas patients who don't respond to standard therapies.
- What could go wrong
- This is a small pilot study with only 45 participants, so results may not apply broadly. The procedure carries surgical risks, and it's unclear if it will outperform existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
45 people
The number who actually took part.
- Started
-
Nov 2018
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with Chagas Disease Cardiomyopathy having an ICD * At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records; * Use of amiodarone and beta blockers in an optimized fashion; * Life expectancy of more than one year * Conditions for following the plan of clinical follow-up of the study. Exclusion criteria: * Presence of an absolute contraindication to receive any of the possible treatments of the study; * Pregnant Woman; * Less than 18 years-old; * Renal insufficiency with creatinine \>2.5 mg/dL (221 umol/L); * Mobile thrombus in the left ventricle; * Left Ventricle Ejection fraction \< 10%; * Unstable angina; * Severe aortic stenosis * Primary severe mitral insufficiency; * New York Heart Association (NYHA) functional class IV; * Previous cardiac surgery or scheduled.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chagas cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, São Paulo, 05403-900, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Armband heart tracker takes on holter monitors
- Heart scans may unlock hidden risks in minority communities
- Could a short course of steroids calm a dangerous heart rhythm?
- Heart device showdown: could CCM beat CRT for chagas patients?
- Can we safely skip the shock test during heart device implant?
- Old gout drug may tame deadly heart inflammation